Tissue Plasminogen Activator for COVID-19-induced Severe Acute Respiratory Distress Syndrome: A Controlled Clinical Trial
The administration of intravenous tPA as 10 mg stat, 40 mg during 2 hours, and 50 mg during the next 10 hours is safe, can cause a rapid relief of dyspnea, and be lifesaving in COVID-19-induced ARDS.
Authors
- Bita Jafarzadeh (ORCID: https://orcid.org/0000-0002-5218-8928)
- Tahereh Madani Motlaq
- Mohammad Vasei (ORCID: https://orcid.org/0000-0002-4162-136X)
- Zeinab Naderpour
- Elham Madreseh (ORCID: https://orcid.org/0000-0002-6987-2179)
- Masoud Solaymani–Dodaran (ORCID: https://orcid.org/0000-0002-1817-5664)
- Vahid Mehrtash (ORCID: https://orcid.org/0000-0003-1187-7580)
- Shahideh Amini (ORCID: https://orcid.org/0000-0002-0543-6183)
- Seyedeh-Esmat Hosseini
- Behzad Khodaei
- Reza Mollazadeh (ORCID: https://orcid.org/0000-0002-2131-0409)
- Neda Pak (ORCID: https://orcid.org/0000-0002-3256-3364)
- Rasoul Aliannejad (ORCID: https://orcid.org/0000-0003-3261-2530)
- Reza Habibi (ORCID: https://orcid.org/0000-0001-6573-7984)
Institutions
- Iran University of Medical Sciences (IR)
- Imam Khomeini Hospital (IR)
- Shariati Hospital (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Infectious Disorders - Drug Targets
- Published
- 2025-01-29
- DOI
- https://doi.org/10.2174/0118715265331792241227173642
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00